Retrospective And Prospective Study Of Benign And Malignant Uterine Corpus Tumours
Benign And Malignant Uterine Corpus Tumer
Keywords:
Benign, Endometrial, Malignant, Tumor, UterineAbstract
Background and Objectives: Uterine tumors may be localized at the corpus, isthmus and cervix. The fallopian tubes and uterine ligaments may also undergo tumor transformation. This study was undertaken to focus on uterine corpus tumors, including benign and malignant tumors. The most common uterine corpus benign tumor is leiomyoma, a proliferation of mesenchymal origin, can be seen at any time between menarche and menopause. Endometrial in on the cancer highest rank amongst genital tract malignancies in the western world but it occupies the lowest rank in the eastern hemisphere including India. Aim :- The study was undertaken to observe prevalence of benign and malignant tumour of uterine corpus according to age and classify according to WHO. Methods: This present retroprospective study was conducted in one of the tertiary care hospital of Meerut city. This study was carried out on 539 cases of female genital tract tumor, out of which 211 cases of uterine tumour during a period of ten years. For the retrospective study all blocks and slides of uterine corpus tumor available were included where as for prospective study hysterectomy specimen of uterus with suspected tumor and biopsies of endometrial tumor were included. The chi square test is applied as test of significance. Results: In our study uterine corpus 194 (71.3%) was most common site for benign tumours in female genital tract, followed by ovary 71 (26.1%), cervix 5 (1.8%) and vagina 2 (0.7%).Where as cervix 193(72.2%) most common site for malignant tumours in female genital tract was followed by ovary 32 (11.9%), uterus 17(6.3%), vagina 16(5.9%), vulva 7(2.6%) and fallopian tubes 2 (0.7%).Most common benign tumor of uterine corpus was leiomyomas 194 cases. Whereas endometrial carcinoma 14(82.3%) most common malignant tumor of uterine corpus after that sarcoma 2(11.7%) and choriocarcinoma 1(5.85%).In age group of 31-40 years maximum cases of benign tumor of uterine corpus was observed whereas maximum cases of malignant tumor of uterine corpus was seen in age group of 51-60 years. Conclusion: The data can be used for estimation of load of the benign and malignant tumours of uterine corpus, establishment of management facilities, as well as for development of the objectives & strategy.
References
genetics of tumours of the breast and Female genital organs. IARC Press: lyon.2002.
2. Mahboubi E, Eyler N, Wynder EL. Epidemiology of cancer of the endometrium. Clin Obstet Gynecol 1982; 25: 5-18.
3. National cancer registry. Annual report 1989. ICMR 1991; 20-33.
4. Shi YF, Xie X, Zhao CL. Histological diagnosis and clinical features in borderline smooth muscle tumors of the uterus. Zhonghua Fu Chan Ke Za Zhi 1994; 29(4):201-4,251.
5. Heinemann K, Thiel C, Mohner S, Lewis MA, Raff T, Kuhl- Habich D, et al. German Cohort Study on Women’s Health Benign gynecological tumors: estimated incidence. Results of the German Cohort Study on Women’s Health. Eur J Obstet Gynecol Reprod Biol 2003; 107(7):78-80.
6. Paymaster J.C. Cancer and its distribution in India. Cancer 1964; 17:1026 – 34.
7. Nkyekyer K. Pattern of gynaecological cancer in Ghana. East Afr Med J 2000; 77 (10): 534-8.
8. Chhabra S, Sonak M, Prem V, Sharma S.Gynaecological malignancies in India .J Obstet Gynaecol 2002; 22(4): 426-9.
9. Kyari O, Nqqada H,Mairiqa A. Malignant tumors of female Genital tract in North Eastern Nigeria . East Afr Med J 2004; 81(3): 142-5.
10. Nwosu S O, Anya S.E. Malignancies of the Female genital tract: a ten years review 1990-1999. Niger Postgrad nud J 2004; 11 (2): 107 – 9.
11. Schraub S, Alauzet E, Schaffer P, Robillard J, Menegoz F. Descriptive Epidemiology of gynecologic and breast cancers. Rev Fr Gynecol Obstet 1992; 87(12): 577-85.
12. Aboyeji A P, Ijaiya MA. Uterine fibroids: a ten-year clinical review in IIorin, Nigeria. Niger J Med 2002; 11 (11): 16-9.
13. Akinyemi B.O, Adewoye B.R, Fakoya T.A. Uterine fibroid. A review .Niger J Med 2004; 13 (4):318 –29.
14. Rammeh-Rommani S, Mokni M, Stita W, Trabelsi A, Hamissa S, Sriha B, et al. Uterine smooth muscle tumors: retrospective epidemiological and pathological study of 2760 cases. J Gynecol Obstet Biol Reprod (Paris) 2005; 34(6):568-71.15. Tan YY, Ho TH. Uterine cancer--KK Hospital experience. Singapore Med J 1996; 37(6):600-3.
16. Parazzini F, La Vecchia C, Bocciolone L, Franceschi S.The epidemiology of endometrial cancer. Gynecol Oncol 1991; 41(1):1-16.
17. Abeler V.M, Kjorstad K.E. Endometrial adenocarcinoma in Norway. A study of a total population. Cancer 1991; 67(12): 3093-103.
18. Platz V.E, Benda J.A: Female genital tract cancer: Cancer 1995; 75: 270 – 294.
19. Greven KM, Com BW. Endometrial cancer. Curr Probl Cancer 1997; 21(2): 65-127.
20. Cavanagn D, Marsden D.E, Ruffolo E.H. Carcinoma of endometrial. Obstet Gynecol Anul 1984; 13:211-60.
21. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005; 366(9484):491-505.
22. Punnonen R, Lauslahti K, Pystynen P, Kauppila O. Uterine sarcoma.Ann Chir Gynaecol Suppl 1985; 197:11-4.
23. Liao Q, Wang J, Han J. Clinical and pathological analysis on 106 cases with uterine sarcoma. Zhonghua Fu Chan Ke Za Zhi 2001; 36(2):104-7.
24. Chang KL, Crabtree GS, Lim –Tan SK, Kempson RL, Hendrickson MR. Primary uterine endometrial stromal neoplasm. A clinicopathological study of 117 cases. Am J Surg Pathol 1990; 14(5):415-38.
25. De Fusco PA,Gaffey TA,Malkasian GD Jr, Long HJ, Cha SS. Endometrial stromal sarcoma: review of Mayo Clinic experience, 1945-1980. Gynecol Oncol 1989; 35(1):8-14.
26. You W, Dainty LA, Rose GS, Krivak T, Metlale MT, Oslen CH, et al. Gynecologic malignancies in women aged less than 25 years. Obstet Gynecol 2005; 105(6): 1405-9.
27. Rose G.S, You W, Oslen C. H. Gynecologic malignancies in women aged less than 25 years. Obstet Gynecol 2005; 105 (6): 1405- 9.
